CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
about
Panton-Valentine leukocidin is not the primary determinant of outcome for Staphylococcus aureus skin infections: evaluation from the CANVAS studiesStaphylococcus aureus - antimicrobial resistance and the immunocompromised child.Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.Ceftaroline fosamil: a brief clinical review.Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA)Early response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections: analysis of the REACH study.Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia.Cutaneous infections and infestations: new therapiesTreatment outcome measures for randomized controlled trials of antibiotic treatment for acute bacterial skin and skin structure infections in the emergency department settingCeftaroline in complicated skin and skin-structure infections.In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme.Systematic Review and Meta-Analysis To Estimate Antibacterial Treatment Effect in Acute Bacterial Skin and Skin Structure Infection.CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolatesTreatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia with Ceftaroline Fosamil in a Patient with Inhalational Thermal Injury.Neutropenia Associated with Long-Term Ceftaroline UseCeftaroline Fosamil Use in 2 Pediatric Patients With Invasive Methicillin-Resistant Staphylococcus aureus Infections.Bacterial cultures, rapid strep test, and antibiotic treatment in infected hard-to-heal ulcers in primary care.Prospective study of the Wilson severity-of-illness scoring system for complicated skin and skin structure infections.Adverse Drug Reactions Associated with Ceftaroline Use: A 2-Center Retrospective Cohort.A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbiLarge retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.Ceftaroline fosamil: a new broad-spectrum cephalosporin.Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections.Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA.Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia.Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.Single- and Repeated-Dose Pharmacokinetics of Ceftaroline in Plasma and Soft Tissues of Healthy Volunteers for Two Different Dosing Regimens of Ceftaroline FosamilEarly response of ceftaroline fosamic in the treatment of soft-tissue infections.Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an in vitro pharmacokinetic model of infection.Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types.Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program.Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study designPharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity.
P2860
Q28729864-E2343AFD-65A9-4D33-BEA6-150F4C67BAFDQ33604961-B0E4DD8C-4E78-4E12-966D-DA4E3238396CQ33657212-DCD90A16-8B1C-4DFB-935C-996C54AC13BAQ33939080-061C8718-958C-46DB-B312-BD108FFC93CEQ34922533-84EA3B5B-9582-4943-A3B5-1FA15F79C5FFQ35117981-78A52AF3-4AD0-419E-8663-A882EB745E7FQ35155399-BC1AEE1A-0113-41C0-84C8-3633C213151AQ35408518-4B480A22-C3CB-4E2F-B150-01B85EC327BDQ35628618-AE92032D-5029-442D-9188-BD1ED5D16DC0Q35656230-F3EF23E1-ABCC-405D-98F0-00FCDFC5F5B8Q35715381-C394AF7D-2C2F-4428-9381-DABA32765D0CQ35822261-87D3A77A-9475-49BB-8E8F-B35000C3BE71Q35860102-9F8E92FA-9C9D-4669-8A4B-B40E19C39878Q35941227-33BD699C-1918-4CA2-948E-1D82F00C4D6BQ35941308-D76692C0-DFAA-4353-A77C-4FBEC45222E9Q36363239-F907F9D5-ACCA-4EE1-A029-9A2F7646956BQ36439140-62721016-D973-49FB-9465-F93148E565A2Q36451698-D040C4D2-7474-46B4-A9F7-C5DC35AC5DD7Q36461712-75CB8236-B158-4185-A5EA-87AB5C92FAE0Q36505476-2BFA1082-30E7-46E7-8094-30DE0570289DQ37080538-7FF61B83-B87F-4F7F-995E-8ABC30F3696AQ37529906-30689540-A16B-45FC-AB9B-FFBB7A5DE116Q37713010-A6CF4AB2-74DA-4EB8-AE6C-33B36B76D7B3Q37863942-2BBED6D6-0AFA-4FD4-A205-DD30B9468722Q38006689-BC092AC0-A1C1-4F24-89EF-055209BFD98DQ38025132-63CD75F1-F3D4-4480-A2B0-9B69E17BA559Q38061168-75112E1D-D305-4C37-AC72-E7D9A3C19A01Q38117077-5224ACDE-7F59-4C3E-890A-FC8E262A6278Q38468392-377C86D6-0410-4756-927E-51CFC84F1714Q38987098-8EC648C2-5419-4048-8479-183619012311Q39226965-8CE798EC-B099-4370-AE4F-E2F70CD6FADEQ39526506-F95687CC-D355-497A-A6E0-CAE8F6815B67Q40804939-38BD9F28-C826-4F25-94C3-F960AA36D298Q41907687-2B555C21-B760-4C07-9841-D8E54FFC0A77Q41919138-16D18DE3-E7AF-4F28-9313-F07D0634F081Q41984202-DA7B1E11-9007-4818-8627-48CAB58E06FFQ42131112-ED8AA635-22E8-4093-B60E-0AD9CFDA93B1Q42275442-EA3E3A04-21ED-4E19-B799-F59FFC01AC41Q42544277-A1E1F942-290C-45D0-A4D2-12768D31F1F6Q42790618-569A1459-4FC0-4E14-921C-72A47FF68BCC
P2860
CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
CANVAS 1: the first Phase III, ...... and skin structure infections.
@en
CANVAS 1: the first Phase III, ...... and skin structure infections.
@en-gb
CANVAS 1: the first Phase III, ...... and skin structure infections.
@nl
type
label
CANVAS 1: the first Phase III, ...... and skin structure infections.
@en
CANVAS 1: the first Phase III, ...... and skin structure infections.
@en-gb
CANVAS 1: the first Phase III, ...... and skin structure infections.
@nl
prefLabel
CANVAS 1: the first Phase III, ...... and skin structure infections.
@en
CANVAS 1: the first Phase III, ...... and skin structure infections.
@en-gb
CANVAS 1: the first Phase III, ...... and skin structure infections.
@nl
P2093
P2860
P356
P1476
CANVAS 1: the first Phase III, ...... and skin structure infections.
@en
P2093
CANVAS 1 investigators
David Friedland
G Ralph Corey
George H Talbot
Tanya Baculik
P2860
P304
P356
10.1093/JAC/DKQ254
P407
P478
65 Suppl 4
P577
2010-11-01T00:00:00Z